Johnson & Johnson files FDA application for CAPLYTA in bipolar mania
The submission seeks approval for adults with manic or mixed episodes linked to bipolar I disorder, an indication the medicine does not currently have. The company points to two Phase 3 studies, in which symptoms improved relative to placebo and the main measures favored treatment at the end of three weeks.
The studies compared once-daily CAPLYTA at this dose with placebo in adults with bipolar I manic episodes.1
The company reported improvement in manic symptoms through the end of the studies' stated treatment period.1
Johnson & Johnson estimates that this many U.S. adults experience bipolar disorder during their lifetimes.1
Story
What the CAPLYTA filing seeks and what the studies reportedJohnson & Johnson has submitted an application to the FDA asking it to approve CAPLYTA for adults experiencing manic or mixed episodes associated with bipolar I disorder.1 The requested use would address episodes that are not among the medicine’s current approved indications: CAPLYTA is not approved to treat bipolar I mania or mixed episodes.1 The company says its submission rests on two pivotal Phase 3 studies that compared the medicine with placebo and reported improvement in manic symptoms.1 The filing is therefore a request for regulatory approval, not evidence that this additional use has already been authorized.1
Both studies evaluated a once-daily 42 mg dose of CAPLYTA against placebo in adults with bipolar I manic episodes, including people whose episodes had mixed features and people whose episodes did not.1 The treatment period in each study lasted three weeks, with patients assigned at random to receive either lumateperone 42 mg once a day or placebo.1 That design let the studies compare outcomes between a treatment group and a placebo group over the same stated period.1 The reported results concern the participants and treatment arrangement described in these studies; the release does not provide participant counts or numerical effect sizes in the facts available here.1
The company reported that manic symptoms improved relative to placebo as early as Day 3, and that the improvement continued through Week 3.1 It also described the early change as appearing after two days of treatment.1 These descriptions refer to the early timing of symptom improvement, while Week 3 marks the period through which the company said improvement was sustained.1 The release does not state a numerical symptom reduction for either the early assessment or the end of treatment in the facts provided here.1
In both studies, CAPLYTA met the primary endpoint and the key secondary endpoint, according to the company.1 The primary measure was the change from the start of the study to Week 3 in total score on the YMRS scale.1 The key secondary measure was the change over the same interval in CGI-S score.1 The company also said the medicine performed better than placebo on mania symptoms and overall illness severity.1 Together, these reported outcomes cover both the specified rating-scale measures at Week 3 and the broader comparisons with placebo described by the company.1
CAPLYTA already has approved adult uses for depressive episodes associated with bipolar I or bipolar II disorder, for schizophrenia, and as an add-on treatment for major depressive disorder.1 Johnson & Johnson says approval for bipolar mania would make this the medicine’s fifth approved use in adults.1 The proposed indication concerns manic or mixed episodes associated with bipolar I disorder, whereas the existing bipolar indication listed by the company concerns depressive episodes.1 The distinction matters to the status of the request: the current approvals do not include the manic or mixed episodes named in the application.1
The company described CAPLYTA as well tolerated in the studies, with few patients stopping treatment and a safety profile it said was consistent with earlier studies.1 Those statements summarize the company’s account of tolerability and discontinuations; the facts provided do not give the rates or detailed safety results.1 John C. Reed said that rapid symptom improvement and tolerability are important considerations when treating people in acute mania.1 His comment connects the timing and tolerability claims to treatment considerations, while the available study facts do not provide a separate clinical recommendation.1
Johnson & Johnson estimates that 11 million adults in the United States experience bipolar disorder at some point during their lives.1 That figure refers to people who experience the disorder over their lives; it is not a count of adults currently having manic episodes or of people enrolled in the studies.1 The company also says manic episodes can worsen quickly and may become severe enough to lead to hospitalization.1 The estimate describes the broader population with bipolar disorder, while the application and trials concern a narrower group: adults with bipolar I manic episodes, with or without mixed features.1
Other Johnson & Johnson developments reported in the cited material concern different products and issues, and do not establish anything about the CAPLYTA studies or FDA decision.234 BioPharma Dive reported a company-announced purchase of Ollin Biosciences for $2.2 billion upfront, with a further $1.1 billion dependent on milestones.2 The same report said Blackstone Life Sciences is providing $750 million for Phase 3 testing of OLN324 in wet age-related macular degeneration and diabetic macular edema.2 These transactions and development plans concern other assets; the facts do not link them to the CAPLYTA application.2
Insurance Journal reported that a Massachusetts jury found Johnson & Johnson baby powder substantially contributed to Winifred Haddad’s mesothelioma and awarded damages for personal injury.3 The jury rejected the wrongful-death claim and did not award punitive damages, according to that report.3 A separate report said the Centers for Medicare & Medicaid Services projected a decrease in the Medicare Advantage weighted average monthly premium, from $14.37 in 2026 to $12.00 in 2027.4 The report also said the FDA granted accelerated approval to RYBREVANT FASPRO on Nov. 5 for certain adults with recurrent or metastatic head and neck squamous cell carcinoma.4 These reports provide wider company and health-policy context, but none changes the stated scope of the CAPLYTA request or the findings reported from its two studies.1234
Structure
Who is connected to whom- 1Johnson & Johnson
- acquires →Fact
- invests in →Fact
- price exposure →Fact
- operates in →Fact
- cost exposure →Fact
Impact
Spreading outward, level by level- Level 1Regulatory status
The submission seeks a new indication; CAPLYTA is not currently approved for bipolar I manic or mixed episodes.1
Fact - Level 2Evidence submitted
The company says two pivotal Phase 3 studies supported the application and met their primary and key secondary endpoints.1
Fact - Level 3Potential adult use
If FDA approval is granted, the requested indication would become a fifth approved adult use, according to the company.1
Fact - Level 4People with acute mania
The filing could matter to treatment options for adults with the specified bipolar I episodes, but the application itself does not establish that the new use is approved.
Analysis
Sources
What each source supportsWritten by AI from the sources listed below: every fact was checked word for word against its source, and inference is marked apart. How we write